An in vitro method for assessing the responsiveness of a patient suffering from solid cancer to antitumoral treatment comprising the steps of: i) determining in a tumor sample obtained from a patient, an expression level of at least one gene representative of human adaptive immune response and an expression level of at least one gene representative of human immunosuppressive response, ii) comparing the expression of said at least one gene representative of human adaptive immune response and said at least one gene representative of human immunosuppressive response determined at step i) with predetermined reference values selected such as said predetermined reference values separate a panel of patients with a cancer into two groupings according to the expression level of said genes and to survival of patients according to Kaplan Meier curves analyses and associated logrank p values; iii) concluding whether the patient has a good, when the level is higher than the predetermined reference value, or a bad, when the level is lower than the predetermined reference value, adaptive immune response and a good or a bad immunosuppressive response iv) determining whether the patient will advantageously receive an antitumoral treatment in view of said good or bad adaptative immune and immunosuppressive responses wherein the at least one gene representative of human adaptive immune response is selected from the group consisting of CCL5 CCR2 CD247 CD3E CD3G CD8A CX3CL1 CXCL11 GZMA GZMB GZMH GZMK IFNG IL15 IRF1 ITGAE PRF1 STAT1 TBX21 and said at least one gene representative of human immunosuppressive response is selected from the group consisting of CD274 CTLA4 IHH IL17A PDCD1 PF4 PROM1 REN TSLP VEGFA i) determining in a tumor sample obtained from a patient, an expression level of at least one gene representative of human adaptive immune response and an expression level of at least one gene representative of human immunosuppressive response, ii) comparing the expression of said at least one gene representative of human adaptive immune response and said at least one gene representative of human immunosuppressive response determined at step i) with predetermined reference values selected such as said predetermined reference values separate a panel of patients with a cancer into two groupings according to the expression level of said genes and to survival of patients according to Kaplan Meier curves analyses and associated logrank p values; iii) concluding whether the patient has a good, when the level is higher than the predetermined reference value, or a bad, when the level is lower than the predetermined reference value, adaptive immune response and a good or a bad immunosuppressive response iv) determining whether the patient will advantageously receive an antitumoral treatment in view of said good or bad adaptative immune and immunosuppressive responses wherein the at least one gene representative of human adaptive immune response is selected from the group consisting of CCL5 CCR2 CD247 CD3E CD3G CD8A CX3CL1 CXCL11 GZMA GZMB GZMH GZMK IFNG IL15 IRF1 ITGAE PRF1 STAT1 TBX21 and said at least one gene representative of human immunosuppressive response is selected from the group consisting of CD274 CTLA4 IHH IL17A PDCD1 PF4 PROM1 REN TSLP VEGFA